Galectin Property Plant And Equipment Gross vs Net Debt Analysis
GALT Stock | USD 2.84 0.07 2.53% |
Galectin Therapeutics financial indicator trend analysis is much more than just examining Galectin Therapeutics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Galectin Therapeutics is a good investment. Please check the relationship between Galectin Therapeutics Property Plant And Equipment Gross and its Net Debt accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Galectin Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Galectin Stock please use our How to Invest in Galectin Therapeutics guide.
Property Plant And Equipment Gross vs Net Debt
Property Plant And Equipment Gross vs Net Debt Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Galectin Therapeutics Property Plant And Equipment Gross account and Net Debt. At this time, the significance of the direction appears to have no relationship.
The correlation between Galectin Therapeutics' Property Plant And Equipment Gross and Net Debt is 0.04. Overlapping area represents the amount of variation of Property Plant And Equipment Gross that can explain the historical movement of Net Debt in the same time period over historical financial statements of Galectin Therapeutics, assuming nothing else is changed. The correlation between historical values of Galectin Therapeutics' Property Plant And Equipment Gross and Net Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Property Plant And Equipment Gross of Galectin Therapeutics are associated (or correlated) with its Net Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Debt has no effect on the direction of Property Plant And Equipment Gross i.e., Galectin Therapeutics' Property Plant And Equipment Gross and Net Debt go up and down completely randomly.
Correlation Coefficient | 0.04 |
Relationship Direction | Positive |
Relationship Strength | Insignificant |
Property Plant And Equipment Gross
Net Debt
The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.Most indicators from Galectin Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Galectin Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Galectin Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Galectin Stock please use our How to Invest in Galectin Therapeutics guide.Enterprise Value is likely to gain to about 104.5 M in 2024, whereas Selling General Administrative is likely to drop slightly above 5.3 M in 2024.
Galectin Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Galectin Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Galectin Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 48.5M | 29.6M | 41.8M | 21.3M | 28.2M | 14.9M | |
Other Current Liab | 1.1M | 4.1M | 7.2M | 9.1M | 9.2M | 9.7M | |
Total Current Liabilities | 2.8M | 5.4M | 9.0M | 13.0M | 15.7M | 16.5M | |
Total Stockholder Equity | 45.6M | 29.6M | 893K | (33.9M) | (60.2M) | (57.2M) | |
Net Debt | (47.4M) | (27.1M) | (10.6M) | 21.3M | 46.1M | 48.5M | |
Retained Earnings | (216.4M) | (240.0M) | (270.7M) | (309.6M) | (354.4M) | (336.7M) | |
Accounts Payable | 1.7M | 1.3M | 1.8M | 3.9M | 6.4M | 6.8M | |
Cash | 47.5M | 27.1M | 39.6M | 18.6M | 25.7M | 13.8M | |
Non Current Assets Total | 258K | 135K | 7K | 733K | 490K | 514.5K | |
Non Currrent Assets Other | 258K | 135K | 7K | 733K | 437K | 458.9K | |
Cash And Short Term Investments | 47.5M | 27.1M | 39.6M | 18.6M | 25.7M | 14.0M | |
Common Stock Shares Outstanding | 52.2M | 57.0M | 58.5M | 59.4M | 60.2M | 63.2M | |
Liabilities And Stockholders Equity | 48.5M | 29.6M | 41.8M | 21.3M | 28.2M | 14.9M | |
Other Stockholder Equity | 259.7M | 261.9M | 271.0M | 275.1M | 293.6M | 308.2M | |
Total Liab | 2.9M | 5.4M | 40.9M | 55.2M | 88.4M | 92.9M | |
Total Current Assets | 48.2M | 29.5M | 41.8M | 20.6M | 27.7M | 14.7M | |
Common Stock | 36K | 41K | 56K | 59K | 61K | 39.3K | |
Property Plant And Equipment Net | 258K | 135K | 7K | 733K | 53K | 50.4K | |
Other Current Assets | 729K | 4.6M | 4.3M | 2.0M | 2.1M | 2.2M | |
Non Current Liabilities Total | 52K | (5.4M) | 31.9M | 42.2M | 72.8M | 76.4M | |
Retained Earnings Total Equity | (181.2M) | (196.2M) | (216.4M) | (240.0M) | (216.0M) | (226.8M) | |
Net Tangible Assets | 45.1M | 21.9M | 366K | (34.4M) | (31.0M) | (29.4M) | |
Capital Surpluse | 173.4M | 194.1M | 259.7M | 261.9M | 301.2M | 200.2M | |
Net Invested Capital | 43.3M | 21.9M | 29.4M | 5.4M | 9.3M | 15.6M | |
Net Working Capital | 45.4M | 24.1M | 32.8M | 7.5M | 12.0M | 20.3M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Galectin Stock Analysis
When running Galectin Therapeutics' price analysis, check to measure Galectin Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Galectin Therapeutics is operating at the current time. Most of Galectin Therapeutics' value examination focuses on studying past and present price action to predict the probability of Galectin Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Galectin Therapeutics' price. Additionally, you may evaluate how the addition of Galectin Therapeutics to your portfolios can decrease your overall portfolio volatility.